Antimicrobial resistance
Adverse outcome pathway
Active pharmaceutical ingredient
Best available techniques
Bioaccumulation factor
Best environmental practices
Contaminants of emerging concern
Canadian Environmental Protection Act
Chemical investigations programme
Oestrone
17β- estradiol
17α- ethinylestradiol
Effect-directed analysis
Endocrine-disrupting chemicals
Environmental impact assessment
Environmentally persistent pharmaceutical pollutants
Extended producer responsibility
Environmental risk assessment
European Union
Environmental quality norm
Environmental quality standard
[U.S.] Food and Drug Administration
Granular activated carbon
Good manufacturing practice
Liquid chromatography–high resolution mass spectrometry
Levonogestrel
Limit of quantification
Minimum selective concentration
No observed adverse effect level
Non-steroidal anti-inflammatory drug
Over-the-counter
Powered activated carbon
Persistent, bioaccumulative and toxic
Predicted environmental concentration
Predicted no effect concentration
Persistent organic pollutants
Pharmaceuticals and personal care products
United Kingdom
United States of America
Very persistent and very bioaccumulative
Water supply, sanitation and hygiene
[EU] Water Framework Directive
World Health Organisation
Water safety plan
Wastewater treatment plant